Pre-made Rontalizumab biosimilar ( Whole mAb, anti-IFNA1 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-494
Anti-IFNA1 therapeutic antibody (Pre-made Rontalizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Rontalizumab is a humanized monoclonal antibody being developed by Genentech. As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.、
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IFNA1 therapeutic antibody (Pre-made Rontalizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Systemic lupus erythematosus|